## Abstract Angiogenesis, the formation of new blood vessels, is controlled by a balance between positive and negative endothelial regulatory factors. Soluble vascular endothelial growth factor receptor‐1 (sVEGFR1), a naturally occurring soluble form of VEGFR1, is a negative counterpart of the vasc
Vascular endothelial growth factor (VEGF) levels and mutation of the BRCA1 gene in breast cancer patients
✍ Scribed by B. Tarnowski; A. Chudecka-Głaz; B. Górski; I. Rzepka-górska
- Publisher
- Springer US
- Year
- 2004
- Tongue
- English
- Weight
- 62 KB
- Volume
- 88
- Category
- Article
- ISSN
- 0167-6806
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Raised plasma VEGF is found in some cancers but levels of its receptor soluble Flt-1 (sFlt-1) are unreported. Hypothesising increased levels to be present in haematological cancers, we measured both by ELISA in 22 patients with haematological cancer, 22 with breast cancer, and in age-and sex-matched
It is known that vascular endothelial growth factor (VEGF) family is an important role in vasculogenesis and angiogenesis. Among the VEGF family members, VEGF-A plays an essential role in angiogenesis. However, the significance of serum levels of other VEGF members (VEGF-C and -D) has been reported
Studies have shown that microvessel density influences breast-cancer prognosis. Since tumor angiogenesis is considered to be substantially affected by the excretion of vascular endothelial growth factor (VEGF) from tumor cells, we examined whether VEGF concentration is different in malignant and in
In this study we genotyped Turkish breast/ovarian cancer patients for BRCA1/BRCA2 mutations: protein truncation test (PTT) for exon 11 BRCA1 of and, multiplex PCR and denaturing gradient gel electrophoresis (DGGE) for BRCA2, complemented by DNA sequencing. In addition, a modified restriction assay w